- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA (2004), EMA (2005))|
|International Nonproprietary Names|
|Avastin® | rhuMAb-VEGF|
|Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Biosimilars: Bevacizumab-awwb (Mvasi®, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
Pfizer's biosimilar (PF-06439535, trade name Zirabev®) received EMA marketing authorisation in April 2019, indicated for specified colorectal, breast, renal, lung, and cervical cancers.
SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882).
CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.
|GtoPdb PubChem SID||178103377|
|Search PubMed clinical trials||bevacizumab|
|Search PubMed titles||bevacizumab|
|Search PubMed titles/abstracts||bevacizumab|